IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v43y2025i1d10.1007_s40273-024-01433-4.html
   My bibliography  Save this article

Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability

Author

Listed:
  • Marcelien H. E. Callenbach

    (Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University)

  • Rick A. Vreman

    (Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University
    National Health Care Institute (ZIN))

  • Christine Leopold

    (Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University)

  • Aukje K. Mantel-Teeuwisse

    (Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University)

  • Wim G. Goettsch

    (Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University
    National Health Care Institute (ZIN))

Abstract

Objective To construct a framework and calculation tool to compare the consequences of implementing different payment models for high-cost, one-off potentially curative therapies and enable decision making to ultimately enhance timely patient access to innovative health interventions. Methods A framework outlining steps to determine potentially suitable payment models was developed. Based on the framework, a supporting calculation tool operationalised as an Excel-based model was constructed to quantify the associated costs for an average patient during the timeframe of the intended payment agreement, the total budget impact and associated benefits expressed in quality-adjusted life-years for the total expected lifetime of the patient population. To demonstrate the potential of the framework, three case studies were used: onasemnogene abeparvovec (Zolgensma®), brexucabtagene autoleucel (Tecartus®) and etranacogene dezaparvovec (Hemgenix®). A hypothetical case study was used to illustrate the output of the calculation tool. Results Part 1 of the framework presents steps for matching a suitable reimbursement and payment model with the disease and treatment characteristics. The reimbursement and payment models are further specified in Part 2. Part 3 guides end users through the setup of a calculation tool with which the financial impact can be calculated of two payment models: a price discount model and an outcome-based spread payment model with a discount. Part 4 concerns the output of the calculation tool, showing how different payment models lead to different financial consequences under three assumptions of longer term effectiveness. Conclusions The presented framework provides decision makers with insight into the financial consequences of their chosen payment model under different assumptions. This can aid reimbursement negotiations by clarifying the optimal choice given a therapy’s characteristics.

Suggested Citation

  • Marcelien H. E. Callenbach & Rick A. Vreman & Christine Leopold & Aukje K. Mantel-Teeuwisse & Wim G. Goettsch, 2025. "Managed Entry Agreements for High-Cost, One-Off Potentially Curative Therapies: A Framework and Calculation Tool to Determine Their Suitability," PharmacoEconomics, Springer, vol. 43(1), pages 53-66, January.
    • Handle: RePEc:spr:pharme:v:43:y:2025:i:1:d:10.1007_s40273-024-01433-4
    DOI: 10.1007/s40273-024-01433-4
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-024-01433-4
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-024-01433-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Simona Gamba & Paolo Pertile & Sabine Vogler, 2020. "The impact of managed entry agreements on pharmaceutical prices," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 47-62, October.
    2. Martin Wenzl & Suzannah Chapman, 2019. "Performance-based managed entry agreements for new medicines in OECD countries and EU member states: How they work and possible improvements going forward," OECD Health Working Papers 115, OECD Publishing.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Constanza Vargas & Rebecca Addo & Milena Lewandowska & Philip Haywood & Richard Abreu Lourenco & Stephen Goodall, 2024. "Use of Health Technology Assessment for the Continued Funding of Health Technologies: The Case of Immunoglobulins for the Management of Multifocal Motor Neuropathy," Applied Health Economics and Health Policy, Springer, vol. 22(1), pages 73-84, January.
    2. Marcelien H. E. Callenbach & Rick A. Vreman & Aukje K. Mantel-Teeuwisse & Wim G. Goettsch, 2022. "When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs," IJERPH, MDPI, vol. 20(1), pages 1-12, December.
    3. Russo, Pierluigi & Carletto, Angelica & Németh, Gergely & Habl, Claudia, 2021. "Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey," Health Policy, Elsevier, vol. 125(9), pages 1140-1145.
    4. Natalie Bohm & Sarah Bermingham & Frank Grimsey Jones & Daniela C. Gonçalves-Bradley & Alex Diamantopoulos & Jessica R. Burton & Hamish Laing, 2022. "The Challenges of Outcomes-Based Contract Implementation for Medicines in Europe," PharmacoEconomics, Springer, vol. 40(1), pages 13-29, January.
    5. Joan Costa‐Font & Rosella Levaggi, 2020. "Innovation, aging, and health care: Unraveling “silver” from “red” herrings?," Health Economics, John Wiley & Sons, Ltd., vol. 29(S1), pages 3-7, October.
    6. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
    7. Jae Ho Jung & Dae Jung Kim & Kangho Suh & Jaeeun You & Je Ho Lee & Kyung In Joung & Dong Churl Suh, 2021. "International Price Comparisons of Anticancer Drugs: A Scheme for Improving Patient Accessibility," IJERPH, MDPI, vol. 18(2), pages 1-14, January.
    8. Hofmarcher, Thomas & Ericson, Oskar & Lindgren, Peter, 2022. "Cancer in Ireland – Disease Burden, Costs and Access to Medicines," IHE Report / IHE Rapport 2022:4, IHE - The Swedish Institute for Health Economics.
    9. Olina Efthymiadou, 2023. "Health technology assessment criteria as drivers of coverage with managed entry agreements: a case study of cancer medicines in four countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(7), pages 1023-1031, September.
    10. Karen M. Facey & Jaime Espin & Emma Kent & Angèl Link & Elena Nicod & Aisling O’Leary & Entela Xoxi & Inneke Vijver & Anna Zaremba & Tatyana Benisheva & Andrius Vagoras & Sheela Upadhyaya, 2021. "Implementing Outcomes-Based Managed Entry Agreements for Rare Disease Treatments: Nusinersen and Tisagenlecleucel," PharmacoEconomics, Springer, vol. 39(9), pages 1021-1044, September.
    11. Pierluigi Russo & Matteo Zanuzzi & Angelica Carletto & Annalisa Sammarco & Federica Romano & Andrea Manca, 2023. "Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service," PharmacoEconomics, Springer, vol. 41(1), pages 107-117, January.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:43:y:2025:i:1:d:10.1007_s40273-024-01433-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.